Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) has received 130 adverse drug reaction reports involving reboxetine (Edronax), including 41 reports of genitourinary disorders that developed within 5 weeks of initiating treatment. In 26 reports, patients experienced symptoms that were consistent with urinary obstruction (hesitancy, retention, dribbling post-micturition and reduced urine flow) and, of those, all but six involved male patients. ADRAC has also received 22 reports of male sexual dysfunction, including erectile dysfunction (n = 4), pain or swelling of the external genitalia or testicles (10) and ejaculation disorders (7), and two reports of women with increased libido. Reboxetine is a selective noradrenaline reuptake inhibitor. ADRAC recommends that, soon after commencing reboxetine treatment, patients should be asked about
symptoms of sexual dysfunction or urinary obstruction.
Adverse Drug Reactions Advisory Committee. Genitourinary symptoms with reboxetine. Australian Adverse Drug Reactions Bulletin, June 2005, 24(3):10.